Brokerages predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report earnings per share (EPS) of ($1.18) for the current quarter, according to Zacks. Four analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.39) and the highest is ($0.80). Alnylam Pharmaceuticals posted earnings per share of ($1.25) in the same quarter last year, which suggests a positive year-over-year growth rate of 5.6%. The company is scheduled to announce its next quarterly earnings report on Friday, May 4th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($5.77) per share for the current fiscal year, with EPS estimates ranging from ($5.90) to ($5.71). For the next year, analysts expect that the company will post earnings of ($4.00) per share, with EPS estimates ranging from ($5.02) to ($3.28). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The firm’s revenue was up 116.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.32) EPS.
Shares of NASDAQ ALNY opened at $98.08 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. The stock has a market cap of $9,749.68, a price-to-earnings ratio of -18.10 and a beta of 2.68. Alnylam Pharmaceuticals has a 12 month low of $48.19 and a 12 month high of $153.99.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 7,221 shares of the stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $136.54, for a total transaction of $985,955.34. Following the completion of the sale, the chief operating officer now owns 7,221 shares of the company’s stock, valued at approximately $985,955.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laurie Keating sold 20,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $145.00, for a total transaction of $2,900,000.00. Following the sale, the senior vice president now directly owns 24,500 shares of the company’s stock, valued at approximately $3,552,500. The disclosure for this sale can be found here. Insiders have sold a total of 198,620 shares of company stock valued at $28,404,143 in the last three months. Insiders own 3.70% of the company’s stock.
Several institutional investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,819,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $4,384,000. Alkeon Capital Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $635,000. Macquarie Group Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 214.5% during the 4th quarter. Macquarie Group Ltd. now owns 40,926 shares of the biopharmaceutical company’s stock worth $5,200,000 after buying an additional 27,914 shares in the last quarter. Finally, Vident Investment Advisory LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $262,000. Hedge funds and other institutional investors own 91.99% of the company’s stock.
WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://weekherald.com/2018/04/18/alnylam-pharmaceuticals-inc-alny-expected-to-post-earnings-of-1-18-per-share.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.